IMG-7289
Phase 2Small molecule
IMG-7289 is one of 8 small molecule programs targeting Essential Thrombocythemia. It is currently in Phase 2.
1
Indications
2
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Essential Thrombocythemia
#DrugCompanyPhaseTrials
1Droxia
TTheravia
Approved
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Trisenox
CCephalon
Approved
Vonjo
SSobi, Inc.
Phase 3
BESREMI
PPharmaEssentia
Phase 3
Bomedemstat
Merck & Co.Phase 3
Inrebic
Bristol-Myers SquibbPhase 3
IMG-7289
TThe University of Texas Health Science Center at San Antonio
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Essential Thrombocythemia2 trials
Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2
Active, not recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04081220·9 enrolled
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
Active, not recruiting·—·Phase 2·NCT04262141·4 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IMG-7289. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details